NDAORALTABLETPriority Review
Approved
Jun 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ERGAMISOL (levamisole HCl) is an oral anthelmintic agent approved by the FDA in 1990 for treating parasitic worm infections. It works by disrupting neuromuscular function in parasites, leading to their paralysis and expulsion. The drug has been used historically for both veterinary and human indications, though its use in humans has become limited.
LOE Approaching
This product is approaching loss of exclusivity with moderate competitive pressure (30%), suggesting a contracting brand team focused on defending residual market share rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ERGAMISOL offers limited career growth opportunities given the product's approaching loss of exclusivity and zero linked job openings. Positions tend to focus on defensive commercialization, generic threat mitigation, and operational efficiency rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on ERGAMISOL at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.